RevBio announced that it has been awarded a $2.2 million Phase II Small Business Innovation Research grant from the National Institute on Aging, part of the National Institutes of Health. This two-year grant builds upon the work that was completed in a prior Phase I grant and will enable the company to complete pre-clinical product testing, which is a key development step for obtaining approval from the U.S. Food & Drug Administration to initiate a human clinical trial.
“Having been involved in the Phase I pre-clinical testing of this product, TETRANITE’s game-changing properties address the limitations which led to the rapid decline in the use of polymethylmethacrylate (PMMA) for spinal fractures,” said Eric Woodard, M.D., Chief of Neurosurgery at the New England Baptist Hospital.
“Kyphoplasty, developed by Kyphon, Inc., was extremely successful in treating chronic pain, which lead to Kyphon’s sale to Medtronic for $3.9 billion,” said Jonathan Slotkin, M.D., practicing neurosurgeon and General Partner at Scrub Capital, which recently made a seed-stage investment in RevBio. “The biomimetic characteristics of TETRANITE provide a much better product profile than PMMA which could make it become the new standard of care—and a blockbuster product—for treating chronic pain associated with spine fractures.”
RevBio announced that it has been awarded a $2.2 million Phase II Small Business Innovation Research grant from the National Institute on Aging, part of the National Institutes of Health. This two-year grant builds upon the work that was completed in a prior Phase I grant and will enable the company to complete pre-clinical product testing,...
RevBio announced that it has been awarded a $2.2 million Phase II Small Business Innovation Research grant from the National Institute on Aging, part of the National Institutes of Health. This two-year grant builds upon the work that was completed in a prior Phase I grant and will enable the company to complete pre-clinical product testing, which is a key development step for obtaining approval from the U.S. Food & Drug Administration to initiate a human clinical trial.
“Having been involved in the Phase I pre-clinical testing of this product, TETRANITE’s game-changing properties address the limitations which led to the rapid decline in the use of polymethylmethacrylate (PMMA) for spinal fractures,” said Eric Woodard, M.D., Chief of Neurosurgery at the New England Baptist Hospital.
“Kyphoplasty, developed by Kyphon, Inc., was extremely successful in treating chronic pain, which lead to Kyphon’s sale to Medtronic for $3.9 billion,” said Jonathan Slotkin, M.D., practicing neurosurgeon and General Partner at Scrub Capital, which recently made a seed-stage investment in RevBio. “The biomimetic characteristics of TETRANITE provide a much better product profile than PMMA which could make it become the new standard of care—and a blockbuster product—for treating chronic pain associated with spine fractures.”
Copy to clipboard 
